• Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 20: 127-130 (1995).

• Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96: 2711-2717 (2001). *

• Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50: 1818-1826 (2009). *

• Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40: 475-483 (2004). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914 (2004). *

• Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368 (2004). *

• Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol. Res. 33: 92-96 (2005).

• Ahima RS. Insulin resistance: cause or consequence of nonalcoholic steatohepatitis? Gastroenterology 132: 444-446 (2007). *

• Ahmed MH. Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers. Scand. J. Gastroenterol. 41: 372 (2006). *

• Ahsan MK, Okuyama H, Hoshino Y, Oka SI, Masutani H, Yodoi J, Nakamura H. Thioredoxin-binding protein-2 deficiency enhances methionine-choline deficient diet-induced hepatic steatosis but inhibits steatohepatitis in mice. Antioxid. Redox Signal. May 18 [Epub ahead of print] (2009).

• Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *

• Akin K, Beyler AR, Kaya M, Erden E. The importance of iron and copper accumulation in the pathogenesis of non-alcoholic steatohepatitis. Turk. J. Gastroenterol. 14: 228-233 (2003). *

• Akyildiz M, Gunsar F, Nart D, Sahin O, Yilmaz F, Akay S, Ersoz G, Karasu Z, Ilter T, Batur Y, Berdeli A, Akarca U. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. Oct 13 [Epub ahead of print] (2009).

• Alazmi W, Bustamante M, O'loughlin C, Gonzalez J, Raskin JB. The association of Streptococcus bovis bacteremia and gastrointestinal diseases: a retrospective analysis. Dig. Dis. Sci. 51: 732-736 (2006). *

• Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 17: 977-986 (2003). *

• Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987-993 (2005). *

• Alisi A, Masotti A, Nobili V. Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. Hepatology 49: 706-707 (2009). *

• Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J. Hepatol. 48: 300-307 (2008).

• Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33 (2006). *

• Amarapurkar A, Ghansar T. Fatty liver: experience from western India. Ann. Hepatol. 6: 37-40 (2007). *

• Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop. Gastroenterol. 25: 130-134 (2004).

• Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann. Hepatol. 7: 148-151 (2008). *

• Amini R, Nosrati N, Yazdanparast R, Molaei M. Teucrium polium in prevention of steatohepatitis in rats. Liver Int. 29: 1216-1221 (2009). *

• Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur. J. Gastroenterol. Hepatol. Oct 31 [Epub ahead of print] (2009).

• Anezaki Y, Ohshima S, Ishii H, Kinoshita N, Dohmen T, Kataoka E, Sato W, Iizuka M, Goto T, Sasaki J, Sasaki T, Suzuki A, Ohnishi H, Horie Y. Sex difference in the liver of hepatocyte-specific Pten-deficient mice: a model of nonalcoholic steatohepatitis. Hepatol. Res. 39: 609-618 (2009). *

• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).

• Angulo P. Treatment of nonalcoholic fatty liver disease. Ann. Hepatol. 1: 12-19 (2002). *

• Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *

• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362 (1999). *

• Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17: 186S-190S (2002). *

• Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16: 797-810 (2002). *

• Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-Ay mice. Hepatology 49: 1636-1644 (2009).

• Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 511-531 (2009).

• Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662-669 (2008). *

• Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51: 371-379 (2009).

• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).

• Asanuma T, Ono M, Kubota K, Hirose A, Hayashi Y, Saibara T, Inanami O, Ogawa Y, Enzan H, Onishi S, Kuwabara M, Oben JA. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut Nov 16 [Epub ahead of print] (2009).

• Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view? J. Hepatol. 51: 212-223 (2009).

• Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 52: 1549-1553 (2005).

• Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol. 3: 27 (2003). *

• Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol. 6: 242-250 (2007). *

• Balaban YH, Sumer H, Simsek H, Us D, Tatar G. Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann. Hepatol. 5: 109-114 (2006). *

• Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 29: 1184-1188 (2009). *

• Banerjee S, Ghosh US, Dutta S. Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. J. Assoc. Physicians India 56: 593-599 (2008).

• Bantel H, Bahr MJ, Schulze-Osthoff K. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis. Hepatology 50: 991 (2009).

• Baranova A, Liotta L, Petricoin E, Younossi ZM. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin. Liver Dis.11: 209-220 (2007).

• Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 194: 539-550 (2007). *

• Bardella MT, Valenti L, Pagliari C, Peracchi M, Fare M, Fracanzani AL, Fargion S. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 36: 333-336 (2004).

• Bass NM. Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic. Hepatology 51: 4-7 (2010). *

• Beath SV. Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346 (2003).

• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307 (2006). *

• Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr. Pract. 13: 300-312 (2007).

• Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 51: 111-120 (2010).

• Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8 Suppl. 1: S4-S8 (2009). *

• Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP, Prieto J. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47: 429-435 (2000). *

• Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57: 655-663 (2008).

• Berg T, Neuhaus R, Klein R, Leder K, Lobeck H, Bechstein WO, Muller AR, Wiedenmann B, Hopf U, Berg PA, Neuhaus P. Distinct enzyme profiles in patients with cryptogenic cirrhosis reflect heterogeneous causes with different outcomes after liver transplantation (OLT): a long-term documentation before and after OLT. Transplantation 74: 792-798 (2002).

• Bernal-Reyes R, Escudero RB. Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Rev. Gastroenterol. Mex. 67: 70-75 (2002).

• Bhattacharya R, Kowdley KV. Iron and HFE mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime? Gastroenterology 125: 615-616 (2003). *

• Blackburn GL, Mun EC. Effects of weight loss surgeries on liver disease. Semin. Liver Dis. 24: 371-379 (2004).

• Boctor FN, Gorak E, Prichard JW, Firouzi M, Difilippo W. Unusual warm autoimmune hemolytic anemia in non-alcoholic steatohepatitis. Ann. Clin. Lab. Sci. 38: 273-276 (2008).

• Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin. Liver Dis.11: 17-23 (2007).

• Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin. Liver Dis. 4: 409-429, vi-vii (2000).

• Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 26: 566-571 (2006). *

• Browning JD. New imaging techniques for non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 607-619 (2009).

• Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99: 292-298 (2004). *

• Bruce KD, Cagampang FR, Argenton M, Zhang J, Ethirajan PL, Burdge GC, Bateman AC, Clough GF, Poston L, Hanson MA, McConnell JM, Byrne CD. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 50: 1796-1808 (2009).

• Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu' G, Martines D. Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G518-G525 (2007). *

• Brun P, Castagliuolo I, Floreani AR, Buda A, Blasone L, Palu G, Martines D. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut 55: 1212 (2006). *

• Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21: 3-16 (2001).

• Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24: 3-20 (2004).

• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94: 2467-2474 (1999). *

• Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 809-820 (2009). *

• Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 35: 1070-1082 (2004).

• Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 16: 49-56 (2003). *

• Brunt EM, Tiniakos DG. Pathological features of NASH. Front. Biosci. 10: 1475-1484 (2005).

• Brunt EM, Wolverson MK, Di Bisceglie AM. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin. Liver Dis. 25: 230-236 (2005).

• Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170 (2005).

• Bugianesi E. Late complications of NASH: a challenge for hepatologists. J. Hepatol. 42: 784-785 (2005).

• Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11: 191-207 (2007).

• Bugianesi E, Bellentani S, Bedogni G, Tiribelli C; Fatty Liver Italian Network. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Ann. Hepatol. 7: 157-160 (2008). *

• Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract. Res. Clin. Gastroenterol. 18: 1105-1116 (2004).

• Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 41: 685-686 (2004). *

• Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am. J. Transplant. 4: 686-693 (2004). *

• Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24: 813-815 (1996). *

• Cabrera R, Nelson DR. Review article: management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31: 461-476 (2010). *

• Caldwell S, Lazo M. Is exercise an effective treatment for NASH? Knowns and unknowns. Ann. Hepatol. 8 Suppl. 1: S60-S66 (2009). *

• Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents. J. Clin. Gastroenterol. 40 Suppl. 1: S61-S66 (2006).

• Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S97-S103 (2004). *

• Caldwell SH, de Freitas LA, Park SH, Moreno ML, Redick JA, Davis CA, Sisson BJ, Patrie JT, Cotrim H, Argo CK, Al-Osaimi A. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 49: 1888-1895 (2009).

• Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 519-525 (2001). *

• Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664-669 (1999). *

• Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916-1923 (2008). *

• Canbakan B, Tahan V, Balci H, Hatemi I, Erer B, Ozbay G, Sut N, Hacibekiroglu M, Imeryuz N, Senturk H. Leptin in nonalcoholic fatty liver disease. Ann. Hepatol. 7: 249-254 (2008). *

• Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z. Gastroenterol. 44: 245-248 (2006).

• Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 34: 685-691 (2008).

• Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 50: 1113-1120 (2009).

• Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem. 18: 184-195 (2007). *

• Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, Bon Homme M, McClain CJ. Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology 51: 474-481 (2010).

• Cayon A, Crespo J, Guerra AR, Pons-Romero F. Gene expression in obese patients with non-alcoholic steatohepatitis. Rev. Esp. Enferm. Dig. 100: 212-218 (2008).

• Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz. J. Med. Biol. Res. 42: 958-962 (2009). *

• Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 1497-1502 (2004). *

• Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37: 544-550 (2003). *

• Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am. J. Gastroenterol. 100: 1317-1321 (2005). *

• Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 50: 143-154 (2009). *

• Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 40 Suppl. 1: S51-S60 (2006).

• Chapman RW. To perform or not to perform liver biopsy: an alternative view. Gut 52: 1227 (2003). *

• Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226 (2007). *

• Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin. Liver Dis.11: 37-54 (2007).

• Charlton M. Fetal obesity syndrome: maternal nutrition as a cause of nonalcoholic steatohepatitis. Hepatology 50: 1696-1698 (2009).

• Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 15: S83-S89 (2009).

• Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, Batts KP. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 7: 608-614 (2001). *

• Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35: 898-904 (2002). *

• Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J, Sarr M. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49: 1375-1384 (2009).

• Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev. 1: CD007340 (2010).

• Chen G, Brunt EM. Diabetic hepatosclerosis: a 10-year autopsy series. Liver Int. 29: 1044-1050 (2009). *

• Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA, Sanyal AJ. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48: 1810-1820 (2008). *

• Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21: 27-41 (2001).

• Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 21: 702-707 (2005).

• Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front. Biosci. 10: 1520-1533 (2005).

• Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur. J. Gastroenterol. Hepatol. 20: 33-36 (2008).

• Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G865-G869 (2001). *

• Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 7: 363-373 (2001). *

• Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 44: 197-208 (2006). *

• Cortez-Pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104 (2004).

• Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 38: 801-804 (2004).

• Cotrim HP, Parana R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am. J. Gastroenterol. 95: 3018-3019 (2000). *

• Crabb DW. Recent developments in alcoholism: the liver. Recent Dev. Alcohol. 11: 207-230 (1993).

• Cua IH, George J. Non-alcoholic fatty liver disease. Hosp. Med. 66: 106-111 (2005).

• Cubelic S, Misak Z, Gasparov S, Kolacek S. Nonalcoholic steatohepatitis in children. Lijec. Vjesn. 126: 197-200 (2004).

• Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 545-563 (2009).

• Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl. Surg. 3: 185-186 (1997).

• Czaja AJ. Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. Dig. Dis. Sci. 43: 1725-1731 (1998). *

• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J. Hepatol. 29: 198-206 (1998). *

• Das K, Kar P. Non-alcoholic steatohepatitis. J. Assoc. Physicians India 53: 195-199 (2005).

• Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur. J. Clin. Nutr. 59: 723-726 (2005).

• David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 1904-1912 (2009). *

• Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 26: 1021-1028 (2006). *

• de Andrade AR, Cotrim HP, Alves E, Soares D, Rocha R, Almeida A, Almeida CG, de Freitas LA. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann. Hepatol. 7: 364-368 (2008).

• de Oliveira CP, de Mello ES, Alves VA, Saviero SM, Strauss E. Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Ann. Hepatol. 6: 255-261 (2007). *

• de Oliveira CP, Stefano JT, de Lima VM, de Sa SV, Simplicio FI, de Mello ES, Correa-Giannella ML, Alves VA, Laurindo FR, de Oliveira MG, Giannella-Neto D, Carrilho FJ. Hepatic gene expression profile associated with non-alcoholic steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice. J. Hepatol. 45: 725-733 (2006). *

• de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165 (2008). *

• Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42: 905-914 (2005). *

• Denk H. Pathology of portal hypertension. J. Gastroenterol. Hepatol. 19: S346-S348 (2004). *

• Denk H, Stumptner C, Fuchsbichler A, Zatloukal K. Mallory bodies and liver diseases. J. Gastroenterol. Hepatol. 19: S349-S352 (2004). *

• Dewitt J, McGreevy K, Cummings O, Sherman S, Leblanc JK, McHenry L, Al-Haddad M, Chalasani N. Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest. Endosc. 69: 535-542 (2009).

• Dhupar R, de Vera ME, Marsh JW, Fontes PA, Steel JL, Zeh HJ, Gamblin TC. Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford) 11: 242-246 (2009). *

• Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand. J. Gastroenterol. 42: 139-147 (2007). *

• Diehl AM. Role of the immune system in the pathogenesis of nonalcoholic steatohepatitis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 78 (2005). *

• Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54: 303-306 (2005). *

• Dixon JB. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis. Clin. Liver Dis.11: 141-154 (2007).

• Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss Hepatology 39: 1647-1654 (2004). *

• Dogru T, Ercin CN, Erdem G, Sonmez A, Tapan S, Tasci I. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103: 3217-3218 (2008). *

• Dogru T, Ercin CN, Erdem G, Sonmez A, Tapan S, Tasci I. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103: 3217-3218 (2008).

• Dogru T, Ercin CN, Erdem G, Tapan S, Tasci I, Sonmez A. Rosiglitazone for nonalcoholic steatohepatitis. Gastroenterology 135: 2156 (2008). *

• Dogru T, Ercin CN, Erdem G, Tasci I, Sonmez A, Tapan S. Nonalcoholic steatohepatitis is frequently accompanied by metabolic diseases. Hepatology 48: 1728 (2008). *

• Dogru T, Ercin CN, Tasci I, Tapan S, Yesilova Z, Uygun A. Orlistat for overweight subjects with nonalcoholic steatohepatitis. Hepatology 49: 2127 (2009).

• Dong H, Wang J, Hirose A, Nozaki Y, Takahashi M, Ono M, Akisawa N, Iwasaki S, Saibara T, Onishi S. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population? J. Hepatol. 46: 915-920 (2007). *

• Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 52: 252-257 (2010). *

• Duclos-Vallee JC, Yilmaz F, Johanet C, Roque-Afonso AM, Gigou M, Trichet C, Feray C, Ballot E, Dussaix E, Castaing D, Bismuth H, Samuel D, Guettier C. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin. Transplant. 19: 591-599 (2005). *

• Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4: 1537-1543 (2006). *

• Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am. J. Gastroenterol. Dec 29 [Epub ahead of print] (2009). *

• Dunn W, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, Malinchoc M, Kamath PS, Shah VH. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131: 1057-1063 (2006). *

• Durazzo M, Niro G, Premoli A, Morello E, Rizzotto ER, Gambino R, Bo S, Musso G, Cassader M, Pagano G, Floreani A. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? J. Gastroenterol. 44: 476-482 (2009). *

• Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian J. Gastroenterol. 23: 12-15 (2004). *

• Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop. Gastroenterol. 25: 15-17 (2004).

• Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin. Liver Dis.11: 75-104 (2007).

• Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873 (2006). *

• El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J. Gastroenterol. 14: 4120-4126 (2008). *

• Elias E. Hepatology highlights. Hepatology 39: 1467-1468 (2004). *

• Elias E. Hepatology highlights. Hepatology 42: 1241-1242 (2005). *

• Ellrichmann M, Vollmer K, Schrader H, Banasch M, Schmidt WE, Meier JJ. Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis. Am. J. Gastroenterol. 104: 3112-3114 (2009).

• Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 48: 2086-2087 (2008). *

• Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 16: 124-128 (2005). *

• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237-267 (2009). *

• Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: 17-26 (2001).

• Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J. Gastroenterol. 11: 2346-2350 (2005). *

• Fargion S, Mattioli M, Fracanzani AL, Fiorelli G. Iron and liver diseases. Can. J. Gastroenterol. 14 Suppl. D: 89D-92D (2000).

• Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 2448-2455 (2001). *

• Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28: 1026-1033 (2008). *

• Farrell GC. Drugs and steatohepatitis. Semin. Liver Dis. 22: 185-194 (2002).

• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112 (2006). *

• Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826 (2004). *

• Feher J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res. 31: 537-551 (2003).

• Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443 (2003). *

• Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front. Biosci. 10: 3093-3099 (2005).

• Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078 (2009).

• Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M. Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54 (2008). *

• Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30: 570-580 (2009). *

• Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309 (2007). *

• Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol. 82: 959-964 (2008). *

• Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5: 513-520 (2007).

• Floreani A. Liver disorders in the elderly. Best Pract. Res. Clin. Gastroenterol. 23: 909-917 (2009).

• Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 103: 1959-1965 (2008). *

• Foschini MP, Macchia S, Losi L, Dei Tos AP, Pasquinelli G, Di Tommaso L, Del Duca S, Roncaroli F, Dal Monte PR. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis. Virchows. Arch. 433: 267-273 (1998). *

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408 (2006). *

• Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, Jung A, Vermeulen W, De Winter B, Pelckmans P, Michielsen P. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int. Oct 13 [Epub ahead of print] (2009). *

• Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 98-105 (2004). *

• Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J. Gastroenterol. 15: 912-918 (2009). *

• Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 50: 772-780 (2009).

• Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S, Saito S, Iwasaki T, Terauchi Y, Nakajima A. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig. Dis. Sci. 52: 3455-3464 (2007). *

• Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Saji Y, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol. Res. 39: 724-738 (2009). *

• Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, Vezozzo DC, Halpern A, Garrido AB Jr, Alves VA, Carrilho FJ. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol. 22: 510-514 (2007). *

• Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, Rigopoulou EI, Dalekos GN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J. Clin. Immunol. 28: 501-511 (2008). *

• Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51 (2004).

• Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 45: 1097-1107 (2007). *

• Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 31: 121-132 (2008). *

• Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, Membrives A, Gallardo-Valverde JM, Munoz-Castaneda JR, Arevalo E, De la Mata M, Muntane J. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 17: 493-503 (2007).

• Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival-death switch. J. Gastroenterol. Hepatol. 21 Suppl. 3: S3-S6 (2006). *

• Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Del Hoyo P, Colina F, Munoz-Yague T, Solis-Herruzo JA. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 44: 581-591 (2006). *

• Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50: 1087-1093 (2009).

• Gaya DR, McLay AL, Oien KA, Spooner RJ, Reilly TG. A tale of two sisters. J. Clin. Pathol. 57: 439-441 (2004). *

• George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59 (2008). *

• Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46 (2007). *

• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15: 942-954 (2009). *

• Ghali P, Lindor KD. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin. Liver Dis. 24: 389-397 (2004).

• Goel R, Boylan B, Gruman L, Newman PJ, North PE, Newman DK. The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet induced-steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1205-G1214 (2007). *

• Gores GJ. Apoptosis and liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 25. September 12 - 13 (2003). *

• Grant LM, Lisker-Melman M. Nonalcoholic fatty liver disease. Ann. Hepatol. 3: 93-99 (2004). *

• Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 9: 271 (2009). *

• Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123: 1367-1384 (2002). *

• Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, Gasbarrini G. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9: 261-263 (2005).

• Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858 (2004). *

• Gyamfi MA, Damjanov I, French S, Wan YJ. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol. 75: 981-995 (2008). *

• Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid. Based Complement. Alternat. Med. Nov 1 [Epub ahead of print] (2009).

• Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022 (2006). *

• Harrison SA. Non-alcoholic steatohepatitis. Preface. Clin. Liver Dis. 13: xiii-xiv (2009). *

• Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49: 80-86 (2009). *

• Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin. Liver Dis. 8: 861-879, ix (2004).

• Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20: 995-1001 (2008).

• Hashimoto E, Taniai M, Yatsuji S, Tokushige K, Shiratori K, Yamamoto M, Fuchinoue S. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S455-S461 (2007). *

• Hashizume H, Sato K, Takagi H, Kanda D, Kashihara T, Kiso S, Mori M. Werner syndrome as a possible cause of nonalcoholic steatohepatitis. J. Clin. Pathol. 62: 1043-1045 (2009).

• Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49: 1563-1570 (2009).

• Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44: 1167-1174 (2006). *

• Heringlake S, Schutte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z. Gastroenterol. 47: 417-423 (2009).

• Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490 (2003).

• Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int. Immunopharmacol. 3: 225-232 (2003).

• Hoekstra M, Li Z, Kruijt JK, Van Eck M, Van Berkel TJ, Kuiper J. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J. Hepatol. 52: 244-251 (2010).

• Holoman J, Glasa J, Galbavy S, Danis D, Molnarova A, Kazar J, Bednarova A, Misianik J. Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases. Bratisl. Lek. Listy. 103: 70-75 (2002).

• Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun. 25: 133-140 (2005).

• Houghton WC. Betaine and nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98: 2803 (2003). *

• Hu ZW, Luo HB, Xu YM, Guo JW, Deng XL, Tong YW, Tang X. Tumor necrosis factor-alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol. Belg. 72: 215-221 (2009).

• Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 100: 1072-1081 (2005). *

• Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 49: 450-465 (2006). *

• Hubscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 16: 1107-1115 (2004).

• Iacono OL, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, Mineo C, De Lisi S, Almasio PL , Craxi A. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am. J. Gastroenterol. 100: 2472-2477 (2005). *

• Ichikawa T, Yanagi K, Motoyoshi Y, Hamasaki K, Nakao K, Toriyama K, Eguchi K. Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J. Gastroenterol. Hepatol. 21: 1865-1866 (2006). *

• Igolnikov AC, Green RM. Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. J. Hepatol. 44: 586-592 (2006). *

• Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Path. Int. 56: 40-45 (2006). *

• Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombes A, Benhamou Y. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 49: 436-442 (2009). *

• Invernizzi P, Bianchi I, Locati M, Bonecchi R, Selmi C. Chapter 7. Cytokines in liver health and disease. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 83-93 (2007). *

• Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J. Hepatol. 50: 562-571 (2009).

• Ito M, Suzuki J, Sasaki M, Watanabe K, Tsujioka S, Takahashi Y, Gomori A, Hirose H, Ishihara A, Iwaasa H, Kanatani A. Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol. Res. 34: 92-98 (2006).

• Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87 (2007). *

• Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol. Sci. 65: 166-176 (2002). *

• Jansen PL. Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis. Ned. Tijdschr. Geneeskd. 149: 289-294 (2005).

• Jansen PL. Non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1079-1085 (2004).

• Jansen PL. Nonalcoholic steatohepatitis. Neth. J. Med. 62: 217-224 (2004). *

• Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 27: 412-421 (2008). *

• Javor ED, Ghany MG, Cochran EK, Oral EA, Depaoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41: 753-760 (2005). *

• Jung MK, Cho HJ, Lee HC, Park KS, Seo EH, Jeon SW, Cho CM, Tak WY, Kim SK, Choi YH, Kweon YO. Comparison of transient elastography and hepatic fibrosis assessed by histology in chronic liver disease. Korean J. Gastroenterol. 51: 241-247 (2008).

• Kadayifci A, Merriman RB, Bass NM. Medical treatment of non-alcoholic steatohepatitis. Clin. Liver Dis.11: 119-140 (2007).

• Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 51: 92-102 (2010). *

• Kajikawa S, Harada T, Kawashima A, Imada K, Mizuguchi K. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. Dig. Dis. Sci. Oct 24 [Epub ahead of print] (2009). *

• Kallwitz ER, Guzman G, Tencate V, Vitello J, Layden-Almer J, Berkes J, Patel R, Layden TJ, Cotler SJ. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am. J. Gastroenterol. 104: 64-69 (2009). *

• Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14: 22-28 (2008). *

• Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 47: 556-564 (2007). *

• Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J. Gastroenterol. 43: 811-822 (2008). *

• Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report. Ryumachi 43: 667-671 (2003).

• Kang Q, Chen A. Curcumin inhibits SREBP-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1. Endocrinology 150: 5384-5394 (2009). *

• Kaplowitz N. Hepatology highlights. Hepatology 39: 271-272 (2004). *

• Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121 (2005). *

• Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 396-406 (2008). *

• Kashireddy PR, Rao MS. Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp. Biol. Med. (Maywood) 229: 158-162 (2004). *

• Kashireddy PV, Rao MS. Lack of peroxisome proliferator-activated receptor a in mice enhances methionine and choline deficient diet-induced steatohepatitis. Hepatol. Res. 30: 104-110 (2004).

• Kawada N. Human hepatic stellate cells are resistant to apoptosis: implications for human fibrogenic liver disease. Gut 55: 1073-1074 (2006). *

• Kawaratani H, Tsujimoto T, Kitazawa T, Kitade M, Yoshiji H, Uemura M, Fukui H. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J. Gastroenterol. 14: 6655-6661 (2008). *

• Keaveny AP, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. Pathol. Int. 55: 660-664 (2005). *

• Keeffe EB, Davis GL. Advances in liver disease: highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42 (2004). *

• Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall Pde L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18: 1272-1282 (2003). *

• Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB; for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Symptoms and quality of life in obese children and adolescents with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 31: 396-406 (2010). *

• Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44: 983-991 (2006). *

• Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003). *

• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321 (2005). *

• Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359 (2010). *

• Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 31: 91-98 (2008). *

• Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin. Liver Dis. 13: 621-630 (2009).

• Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150 (2005).

• Komatsu M, Yazaki M, Tanaka N, Sano K, Hashimoto E, Takei YI, Song YZ, Tanaka E, Kiyosawa K, Saheki T, Aoyama T, Kobayashi K. Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J. Hepatol. 49: 810-820 (2008). *

• Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328: 116-122 (2009). *

• Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, Lochs H, Strasburger CJ, Stewart PM, Quinkler M. Hepatic 11beta-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis. Clin. Endocrinol. (Oxf.) 70: 554-560 (2009). *

• Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 41: 592-588 (2004). *

• Koteish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16: 679-690 (2002).

• Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am. J. Gastroenterol. 101: 1370-1378 (2006). *

• Kroy DC, Beraza N, Tschaharganeh DF, Sander LE, Erschfeld S, Giebeler A, Liedtke C, Wasmuth HE, Trautwein C, Streetz KL. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology 51: 463-473 (2010). *

• Krueger KJ, McClain CJ, McClave SA, Dryden GW. Nutritional supplements and alternative medicine. Curr. Opin. Gastroenterol. 20: 130-138 (2004).

• Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J. Hepatol. 51: 168-175 (2009).

• Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 29: 988-996 (2009). *

• Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin. Proc. 75: 733-739 (2000). *

• Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42: 650-656 (2005). *

• Kwon DY, Jung YS, Kim SJ, Park HK, Park JH, Kim YC. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J. Nutr. 139: 63-68 (2009). *

• Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 48: 821-828 (2008).

• Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and chemokines in the development of steatohepatitis. Semin. Liver Dis. 27: 173-193 (2007).

• Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann. Hepatol. 8 Suppl. 1: S51-S59 (2009). *

• Lang L. Phase I/II clinical trial to explore silymarin in chronic liver diseases. Gastroenterology 131: 990 (2006). *

• Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 23: 1635-1648 (2008). *

• Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, Dela Pena A, Bell-Anderson KS, Farrell GC. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J. Gastroenterol. Hepatol. 23: 267-275 (2008). *

• Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chereau C, Conti F, Jaffray P, Soubrane O, Calmus Y, Weill B, Batteux F. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 39: 1277-1285 (2004). *

• Leclercq IA. Pathogenesis of steatohepatitis: insights from the study of animal models. Acta Gastroenterol. Belg. 70: 25-31 (2007).

• Leclercq IA, Farrell GC, Sempoux C, Pena AD, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41: 926-934 (2004). *

• Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 47: 239-244 (2007). *

• Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, Sturek M, Chalasani N. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 50: 56-67 (2009). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 20: 188-197 (2004).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 19: 185-193 (2003).

• Lefkowitch JH. Liver histopathology. Clin. Liver Dis. 6: xv-xix (2002). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 22: 198-208 (2006).

• Lefkowitch JH. Morphology of alcoholic liver disease. Clin. Liver Dis. 9: 37-53 (2005).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 24: 269-277 (2008).

• Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. Liver Int. 26: 559-565 (2006). *

• Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 20: 387-395 (2006). *

• Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 29: 1431-1438 (2009). *

• Lengyel G, Tulassay Z. Antioxidant therapy in chronic liver diseases. Orv. Hetil. 147: 1113-1118 (2006).

• Levinthal GN, Tavill AS. Liver disease and diabetes mellitus. Clinical Diabetes 17: 73 (1999). *

• Li X, Han de W, Zhao LF, Yin L. Effect of endotoxin on the expression of peroxisome proliferator-activated receptor alpha in the development of nonalcoholic steatohepatitis in rats. Zhonghua Gan Zang Bing Za Zhi 13: 89-91 (2005).

• Li X, Zhang Y, Wu K, Fan D. Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis. Hepatology Nov 13 [Epub ahead of print] (2009). *

• Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3: 321-331 (2006). *

• Li Z, Diehl AM. Innate immunity in the liver. Curr. Opin. Gastroenterol. 19: 565-571 (2003).

• Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, Thomas SA, Diehl AM. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 40: 434-441 (2004). *

• Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).

• Lieber CS. CYP2E1: from ASH to NASH. Hepatol. Res. 28: 1-11 (2004).

• Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 36: 511-529 (2004). *

• Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr. Gastroenterol. Rep. 6: 60-65 (2004).

• Lieber CS, Decarli LM, Leo MA, Mak KM, Ponomarenko A, Ren C, Wang X. Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH. J. Hepatol. 48: 318-326 (2008). *

• Lieber CS, Leo MA, Cao Q, Mak KM, Ren C, Ponomarenko A, Wang X, Decarli LM. The combination of S-adenosylmethionine and dilinoleoylphosphatidylcholine attenuates non-alcoholic steatohepatitis produced in rats by a high-fat diet. Nutr. Res. 27: 565-573 (2007). *

• Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 79: 502-509 (2004). *

• Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 27: 76-80 (2007). *

• Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770-778 (2004). *

• Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 48: 569-572 (2009).

• London RM, George J. Pathogenesis of NASH: animal models. Clin. Liver Dis.11: 55-74 (2007).

• Loomba R, Kleiner DE, Hoofnagle JH. Mechanism of action of metformin in nonalcoholic steatohepatitis: authors' reply. Aliment. Pharmacol. Ther. 29: 603-604 (2009).

• Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50: 1282-1293 (2009). *

• Lopez Dieguez Puerta M, Casal Esteban V, Barbado Hernandez FJ, Gil Guerrero L, Rodriguez Molinero MA, Larrauri J, Vazquez Rodriguez JJ. Nonalcoholic steatohepatitis, the enigma of bad progress. An. Med. Interna. 22: 85-87 (2005).

• Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig. Dis. 23: 72-82 (2005).

• Ludtke A, Genschel J, Brabant G, Bauditz J, Taupitz M, Koch M, Wermke W, Worman HJ, Schmidt HH. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100: 2218-2224 (2005). *

• Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 12: 398-403 (1997).

• Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132 (2007). *

• Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat. Rev. Gastroenterol. Hepatol. 6: 679-683 (2009).

• Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46: 1519-1529 (2007). *

• Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T, Baldeiras I, Camilo ME, Cortez-Pinto H. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand. J. Gastroenterol. 43: 95-102 (2008). *

• Mackay IR. Foreword. Contemporary liver immunology and immunopathology: obstacles and opportunities. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 1-14 (2007). *

• Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48: 670-678 (2008). *

• Maheshwari A, Thuluvath PJ. Cryptogenic cirrhosis and NAFLD: are they related? Am. J. Gastroenterol. 101: 664-668 (2006). *

• Maier KP. The patient with slightly increased liver function tests. Schweiz. Rundsch. Med. Prax. 94: 139-143 (2005).

• Malaguarnera L, Di Rosa M, Zambito AM, dell'Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells of non-alcoholic fatty liver disease patients. Gut 55: 1313-1320 (2006). *

• Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *

• Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. Chin. J. Dig. Dis. 8: 58-64 (2007). *

• Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7: 800-806 (2009).

• Malinska H, Oliyarnyk O, Hubova M, Zidek V, Landa V, Simakova M, Mlejnek P, Kazdova L, Kurtz TW, Pravenec M. Increased liver oxidative stress and altered PUFA metabolism precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis. Mol. Cell. Biochem. Sep 12 [Epub ahead of print] (2009). *

• Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, Vanni E, Manini R, Rizzetto M, Melchionda N. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res. Clin. Pract. 63: 143-151 (2004).

• Marchesini G, Suppini A, Forlani G. NAFLD treatment: cognitive-behavioral therapy has entered the arena. J. Hepatol. 43: 926-928 (2005). *

• Marra F. NASH: are genes blowing the hits? J. Hepatol. 40: 853-856 (2004). *

• Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, Kanel G, Avila MA, Mato JM, Lu SC. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16: 1292-1294 (2002). *

• Mas E, Danjoux M, Garcia V, Carpentier S, Segui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 4: e7929 (2009). *

• Mascitelli L, Pezzetta F, Goldstein MR. Mechanism of action of metformin in nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 29: 602-603 (2009). *

• Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand. J. Gastroenterol. 34: 85-91 (1999). *

• Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. HPB (Oxford) 9: 312-318 (2007). *

• Matsumoto T, Suzuki N, Watanabe H, Irie M, Iwata K, Anan A, Nakane H, Yoshikane M, Nishizawa S, Sohda T, Sakisaka S. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 39: 1102-1105 (2004). *

• Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46: 1392-1403 (2007). *

• Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-Halimi M, Handem I, Grammer AC, Lipsky PE. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int. 26: 1871-96 (2006). *

• McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol 34: 67-79 (2004). *

• McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis - promising but not ready for prime time. N. Engl. J. Med. 355: 2361-2363 (2006). *

• Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev. 60: 289-293 (2002).

• Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opin. Investig. Drugs 14: 29-35 (2005).

• Mendez-Sanchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M. Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Ann. Hepatol. 2: 183-185 (2003). *

• Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martinez L, Chavez-Tapia NC, Baptista-Gonzalez HA, Uribe M. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int. 27: 215-219 (2007). *

• Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 96: 1631-1634 (2001). *

• Mensink RP, Plat J, Schrauwen P. Diet and nonalcoholic fatty liver disease. Curr. Opin. Lipidol. 19: 25-29 (2008).

• Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 40 Suppl. 1: S30-S33 (2006).

• Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; The Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. J. Gastroenterol. Sep 30 [Epub ahead of print] (2009). *

• Milke Garcia Mdel P. Ghrelin: beyond hunger regulation. Rev. Gastroenterol. Mex. 70: 465-474 (2005).

• Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 49: 1926-1934 (2009).

• Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, De Vera ME, Gruttadauria S, Miraglia R, Pipitone L, Marsh JW, Marcos A, Gridelli B, Demetris AJ. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests? J. Hepatol. 50: 501-510 (2009).

• Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr. Drug Discov. Technol. 4: 133-140 (2007).

• Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol. Res. 39: 366-373 (2009). *

• Moreno Sanchez D. Pathogenesis of primary nonalcoholic fatty liver disease. Med. Clin. (Barc.) 124: 668-677 (2005).

• Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 52: 1338-1343 (2005).

• Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 41: 204 (2005). *

• Mu Y, She R, Zhang H, Dong B, Huang C, Lin W, Li D, Li X. Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats. Hepatol. Res. 39: 910-920 (2009). *

• Mulhall BP, Younossi ZM. Nonalcoholic steatohepatitis. Curr. Treat. Options Gastroenterol. 7: 423-430 (2004).

• Muller T, Langner C, Fuchsbichler A, Heinz-Erian P, Ellemunter H, Schlenck B, Bavdekar AR, Pradhan AM, Pandit A, Muller-Hocker J, Melter M, Kobayashi K, Nagasaka H, Kikuta H, Muller W, Tanner MS, Sternlieb I, Zatloukal K, Denk H. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology 39: 963-969 (2004). *

• Munoz L, Cordero P. Adipokines in nonalcoholic steatohepatitis. Liver Int. Nov 30 [Epub ahead of print] (2009). *

• Munoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. Ann. Hepatol. 8: 123-128 (2009). *

• Munoz-Espinosa LE, Martinez-Garcia A, del Castillo O, Cordero-Perez P, Caballero-Mendoza E, Perez-Rodriguez E, Hernandez Guedea MA, Elizondo-Riojas G, Escobedo-Villarreal M. Posttransplant relapse in non viral hepatopathies. Gac. Med. Mex. 144: 403-408 (2008).

• Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Cassader M, Durazzo M, Rizzetto M, Pagano G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 100: 2438-2446 (2005). *

• Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am. J. Clin. Nutr. 86: 661-671 (2007). *

• Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am. J. Clin. Nutr. 89: 558-567 (2009). *

• Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 49: 426-435 (2009). *

• Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann. Hepatol. 8 Suppl. 1: S25-S33 (2009). *

• Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 32: 453-468 (2007). *

• Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 20: 23-28 (2004). *

• Nakajima A, Yoneda M, Takahashi H, Fujisawa N, Wada K. The roles of PPARs in digestive diseases. Nippon Rinsho 63: 665-671 (2005).

• Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An JL, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30: 41-49 (2008). *

• Nakano S, Nagasawa T, Ijiro T, Inada Y, Tamura T, Maruyama K, Kuroda J, Yamazaki Y, Kusama H, Shibata N. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol. Res. 38: 1026-1039 (2008). *

• Nakayama H, Otabe S, Yuan X, Ueno T, Hirota N, Fukutani T, Wada N, Hashinaga T, Yamada K. Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metabolism 58: 901-908 (2009). *

• Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40: 781-786 (2004). *

• Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 8: 613-618 (2004). *

• Nanji AA. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis. 8: 559-574, ix (2004).

• Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46: 2347-2352 (2001). *

• Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl. 11: S63-S68 (2005). *

• Neuschwander-Tetri BA. Nonalcoholic steatohepatitis. Clin. Liver Dis. 2: 149-173 (1998).

• Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr. Gastroenterol. Rep. 4: 31-36 (2002).

• Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. Can. J. Gastroenterol. 14: 321-326 (2000). *

• Neuschwander-Tetri BA. Fatty liver and nonalcoholic steatohepatitis. Clin. Cornerstone 3: 47-57 (2001).

• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-10017 (2003). *

• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 38: 434-440 (2003). *

• Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219 (2003). *

• Niwa H, Sasaki M, Haratake J, Kasai T, Katayanagi K, Kurumaya H, Masuda S, Minato H, Zen Y, Uchiyama A, Miwa A, Saito K, Sudo Y, Nakanuma Y. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol. Res. 37: 923-931 (2007). *

• No authors listed. Capabilities of complex therapy of chronic biliary pancreatitis against background of obesity using multinutrient functional complexes "Grinization". Lik. Sprava. 3-4: 13-21 (2009).

• Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48: 442-448 (2008). *

• Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 133: 608-618 (2007). *

• Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, Wakui Y, Kido O, Ninomiya M, Kogure T, Inoue J, Kondo Y, Shiina M, Iwasaki T, Yamamoto T, Shimosegawa T. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J. Gastroenterol. 43: 720-728 (2008). *

• Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S, Yoshida S. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol. Rep. 10: 1473-1478 (2003).

• Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M. Visceral fat accumulation is an independent risk factor of hepatocellular carcinoma recurrence after curative treatment in NASH-suspected patients. Gut 58: 839-844 (2009).

• Ohnishi T, Ogawa Y, Saibara T, Nishioka A, Kariya S, Fukumoto M, Onishi S, Yoshida S. CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol. Res. 33: 178-180 (2005).

• Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis.11: 1-16 (2007).

• Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin. Liver Dis. 9: 617-634 (2005).

• Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 1: CD005160 (2007). *

• Oruc N, Ozutemiz O, Berdeli A, Ersoz G, Gunsar F, Karasu Z, Ilter T, Batur Y, Akarca US. Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease. Ann. Hepatol. 8: 116-119 (2009). *

• Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132: 282-293 (2007). *

• Ouazzani-Chahdi A, Elimadi A, Chabli A, Spenard J, Colin P, Haddad PS. Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity. Can. J. Physiol. Pharmacol. 85: 233-242 (2007).

• Oz HS, Im HJ, Chen TS, de Villiers WJ, McClain CJ. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J. Biochem. Mol. Toxicol. 20: 39-47 (2006). *

• Pagadala M, Zein CO, McCullough AJ. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin. Liver Dis. 13: 591-606 (2009).

• Page JM, Harrison SA. NASH and HCC. Clin. Liver Dis. 13: 631-647 (2009).

• Papakyriakou P, Tzardi M, Valatas V, Kanavaros P, Karydi E, Notas G, Xidakis C, Kouroumalis E. Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis 7: 133-141 (2002). *

• Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J. Hepatol. 51: 931-938 (2009).

• Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J. Clin. Endocrinol. Metab. 93: 26-31 (2008). *

• Parola M, Novo E. Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. J. Hepatol. 43: 1096-1097 (2005). *

• Patton H, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135: 1961-1971.e2 (2008). *

• Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 22 Suppl. 1: S20-S27 (2007). *

• Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1095-1105 (2004).

• Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G193-G199 (2002). *

• Pillai AA, Rinella ME. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin. Liver Dis. 13: 689-710 (2009).

• Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46: 324-329 (2007). *

• Pogribny IP, Tryndyak VP, Bagnyukova TV, Melnyk S, Montgomery B, Ross SA, Latendresse JR, Rusyn I, Beland FA. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J. Hepatol. 51: 176-186 (2009).

• Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692 (2000). *

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. The emerging problem of nonalcoholic steatohepatitis (NASH). Rom. J. Gastroenterol. 14: 43-51 (2005).

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem. 38: 203-217 (2005). *

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr. Med. Chem. 13: 2889-2900 (2006).

• Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51: 121-129 (2010).

• Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50: 1827-1838 (2009).

• Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat. Dis. Int. 4: 173-177 (2005). *

• Rahman SM, Schroeder-Gloeckler JM, Janssen RC, Jiang H, Qadri I, Maclean KN, Friedman JE. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 45: 1108-1117 (2007). *

• Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J. Hepatol. 42 Suppl.: S2-S12 (2005). *

• Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int. 26: 1000-1005 (2006). *

• Rao MS, Papreddy K, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. In Vivo 16: 145-152 (2002).

• Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver Dis. 21: 43-55 (2001).

• Raso GM, Esposito E, Iacono A, Pacilio M, Cuzzocrea S, Canani RB, Calignano A, Meli R. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur. J. Pharmacol. 604: 125-131 (2009).

• Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T; LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51: 445-453 (2010). *

• Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906 (2005). *

• Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44: 802-805 (2006). *

• Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 667-688 (2009).

• Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol. 14: 185-192 (2008). *

• Reddy JK, Sambasiva Rao M. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G852-G858 (2006). *

• Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723 (2001). *

• Reid BM, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1117-1122 (2004).

• Rensen SS, Slaats Y, Driessen A, Peutz-Kootstra CJ, Nijhuis J, Steffensen R, Greve JW, Buurman WA. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 50: 1809-1817 (2009). *

• Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99: 1708-1717 (2004). *

• Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of steatohepatitis in mice fed a lipogenic methionine choline deficient (MCD) diet. J. Lipid Res. 49: 1068-1076 (2008). *

• Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47: 571-579 (2007). *

• Roberts EA. Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 5: 253-259 (2003).

• Roberts EA. Non-alcoholic steatohepatitis in children. Clin. Liver Dis.11: 155-172 (2007).

• Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G1135-G1139 (2001). *

• Rodriguez-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodriguez-Moran M, Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur. J. Gastroenterol. Hepatol. 20: 399-403 (2008).

• Rosa H, Parise ER. Is there a place for serum laminin determination in patients with liver disease and cancer? World J. Gastroenterol. 14: 3628-3632 (2008). *

• Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822 (2006). *

• Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1220-1222 (2004). *

• Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int. 21: 459-465 (2008). *

• Rubio A, Guruceaga E, Vazquez-Chantada M, Sandoval J, Martinez-Cruz LA, Segura V, Sevilla JL, Podhorski A, Corrales FJ, Torres L, Rodriguez M, Aillet F, Ariz U, Caballeria J, Martin-Duce A, Lu SC, Martinez-Chantar ML, Mato JM. Gene-pathway identification associated with non-alcoholic steatohepatitis. J. Hepatol. 46: 708-718 (2007). *

• Saab S, Cho D, Lassman RC, Gajjar NA, Ghobrial M, Busuttil RW. Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. J. Hepatol. 42: 148-149 (2005). *

• Saibara T, Namikawa C, Zhang SP, Nozaki Y, Yoshihisa N, Ono M, Akisawa N, Iwasaki S, Onishi S, Hiroi M, Enzan H. Functional genetic polymorphisms of microsomal triglyceride transfer protein and manganase-SOD in nonalcoholic steatohepatitis and primary biliary cirrhosis. J. Hepatol. 40 Suppl. 1: 175 (2004).

• Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 11: 255-259 (2005). *

• Salt WB 2nd. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J. Insur. Med. 36: 27-41 (2004).

• Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc. Natl. Acad. Sci. U.S.A. 100: 3065-3070 (2003). *

• Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 46-53 (2005). *

• Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am. J. Gastroenterol. 96: 274-276 (2001). *

• Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183-1192 (2001). *

• Sasaki M, Ikeda H, Nakanuma Y. Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21(WAF1/Cip1) in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. J. Autoimmun. 31: 73-78 (2008).

• Sasaki M, Ikeda H, Yamaguchi J, Miyakoshi M, Sato Y, Nakanuma Y. Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with fibrous progression. Am. J. Clin. Pathol. 133: 212-223 (2010).

• Sasaki N, Ueno T, Morita Y, Nagata E, Sata M. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 53: 678-681 (2006).

• Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig. Dis. Sci. 50: 171-180 (2005). *

• Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 1946-1952 (2004). *

• Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 447: 996-999 (2005). *

• Sato N. Central role of mitochondria in metabolic regulation of liver pathophysiology. J. Gastroenterol. Hepatol. 22 Suppl. 1: S1-S6 (2007). *

• Savransky V, Bevans S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G871-G877 (2007). *

• Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 53: 3218-3224 (2008). *

• Sazci A, Ergul E, Aygun C, Akpinar G, Senturk O, Hulagu S. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell. Biochem. Funct. 26: 291-296 (2008). *

• Schartman J, Weinstein J. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis. Hepatology 43: 882-883 (2006). *

• Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ. Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology 43: 163-172 (2006). *

• Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol. Res. 39: 972-978 (2009). *

• Schotanus BA, van den Ingh TS, Penning LC, Rothuizen J, Roskams TA, Spee B. Cross-species immunohistochemical investigation of the activation of the liver progenitor cell niche in different types of liver disease. Liver Int. 29: 1241-1252 (2009). *

• Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z. Gastroenterol. 46: 1369-1371 (2008).

• Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 130: 1886-1900 (2006). *

• Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51: 433-445 (2009).

• Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42: 641-649 (2005). *

• Seki E, Brenner DA. The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor? J. Hepatol. 47: 307-309 (2007). *

• Sepulveda-Flores RN, Vera-Cabrera L, Flores-Gutierrez JP, Maldonado-Garza H, Salinas-Garza R, Zorrilla-Blanco P, Bosques-Padilla FJ. Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity. Ann. Hepatol. 1: 36-39 (2002). *

• Serfaty L. Pioglitazone: the beginning of a new era for NASH? J. Hepatol. 47: 160-162 (2007). *

• Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 13: 966-974 (2007). *

• Sharma MR, Polavarapu R, Roseman D, Patel V, Eaton E, Kishor PB, Nanji AA. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. Exp. Mol. Pathol. 81: 202-210 (2006). *

• Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7s level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 102: 1931-1938 (2007). *

• Shiota G. Adiponectin as a therapeutic target of non-alcoholic steatohepatitis. Hepatol. Res. 39: 951-953 (2009). *

• Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol. 44: 732-741 (2006). *

• Siatkosky LL, Shermock KM, Younossi ZM. Investigational pharmacologic treatment for liver disease. Expert Opin. Investig. Drugs 11: 1281-1293 (2002).

• Simonovic-Babic J, Delic D, Svirtlih N, Dordevic M. Elevated aminotransferse levels - diagnostic approach. Med. Pregl. 57: 429-433 (2004).

• Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28 year follow up. Hepatology 51: 595-602 (2010). *

• Solga SF. Probiotics can treat hepatic encephalopathy. Med. Hypotheses 61: 307-313 (2003). *

• Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 94: 1018-1022 (1999). *

• Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am. J. Gastroenterol. 95: 3206-3210 (2000). *

• Soresi M, Bonfissuto G, Magliarisi C, Riili A, Terranova A, Di Giovanni G, Bascone F, Carroccio A, Tripi S, Montalto G. Ultrasound detection of abdominal lymph nodes in chronic liver diseases. A retrospective analysis. Clin. Radiol. 58: 372-377 (2003). *

• Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R. Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol. 41: 751-757 (2004). *

• Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. Oct 27 [Epub ahead of print] (2009). *

• Speliotes EK. Genetics of common obesity and nonalcoholic fatty liver disease. Gastroenterology 136: 1492-1495 (2009). *

• Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38: 244-251 (2003). *

• Stefano JT, de Oliveira CP, Correa-Giannella ML, de Lima VM, de Sa SV, de Oliveira EP, de Mello ES, Giannella-Neto D, Alves VA, Carrilho FJ. Nonalcoholic steatohepatitis (NASH) in OB/OB mice treated with Yo Jyo Hen Shi Ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig. Dis. Sci. 52: 3448-3454 (2007). *

• Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv. Ther. 26: 893-907 (2009). *

• Strnad P, Zatloukal K, Stumptner C, Kulaksiz H, Denk H. Mallory-Denk bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim. Biophys. Acta 1782: 764-774 (2008). *

• Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108: 9-13 (2000). *

• Su WJ, Chen HL, Lai HS, Ni YH, Chang MH. Pancreaticobiliary anomalies is the leading cause of childhood recurrent pancreatitis. J. Formos. Med. Assoc. 106: 119-125 (2007). *

• Sugimoto M, Sadamoto T, Nonaka H. Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi 38: 34-45 (2003).

• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol. Res. 39: 213-222 (2009).

• Sundaram SS, Whitington PF, Green RM. Steatohepatitis develops rapidly in transgenic mice over-expressing Abcb11 fed a methionine-choline deficient diet. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1321-G1327 (2005). *

• Suriawinata A, Fiel MI. Liver pathology in obesity. Semin. Liver Dis. 24: 363-370 (2004).

• Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 26: 1209-1216 (2006). *

• Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 169: 846-860 (2006). *

• Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 565-580 (2009).

• Syn WK, Yang L, Chiang D, Qian Y, Jung Y, Karaca G, Choi SS, Witek RP, Omenetti A, Pereira TA, Diehl AM. Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int. 29: 1262-1272 (2009). *

• Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of Toll-like receptors 2 and 4. Alcohol Clin. Exp. Res. 29: 140S-145S (2005).

• Tacikowski T, Nowicka G, Bujko J, Walewska-Zielecka B, Dzieniszewski J. Influence of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development. Pol. Arch. Med. Wewn. 113: 213-222 (2005).

• Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132: 938-943 (2007). *

• Talwalkar JA. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology 50: 1000-1003 (2009). *

• Tanaka N, Aoyama T. PPAR and NASH. Nippon Rinsho 64: 1089-1094 (2006).

• Tanaka N, Ichijo T, Okiyama W, Mutou H, Misawa N, Matsumoto A, Yoshizawa K, Tanaka E, Kiyosawa K. Laparoscopic findings in patients with nonalcoholic steatohepatitis. Liver Int. 26: 39-45 (2006). *

• Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42: 413-418 (2008).

• Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Horiuchi A, Kiyosawa K. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 26: 956-963 (2006). *

• Taniai M, Hashimoto E, Tobari M, Yatsuji S, Haruta I, Tokushige K, Shiratori K. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol. Res. 39: 685-693 (2009). *

• Tannapfel A, Reinacher-Schick A. Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC). Z. Gastroenterol. 46: 435-440 (2008).

• Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J. Gastroenterol. Hepatol. 22: 293-303 (2007). *

• te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur. J. Intern. Med. 15: 10-21 (2004). *

• Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J. Gastroenterol. 14: 4771-4775 (2008). *

• Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury. Hepatology Nov 9 [Epub ahead of print] (2009). *

• Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z. Gastroenterol. 45: 63-70 (2007).

• Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343: 1467-1476 (2000). *

• Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 148-155 (2005). *

• Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 16: 770-776 (2008). *

• Tokushige K. Diagnosis and therapy in NASH. Rinsho Byori 57: 848-853 (2009).

• Tokushige K, Hashimoto E, Noto H, Yatsuji S, Tobari M, Torii N, Taniai M, Shiratori K, Murayama H. Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis. Hepatol. Res. 39: 939-943 (2009). *

• Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46: 1104-1110 (2007). *

• Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther. Clin. Risk Manag. 3: 1153-1163 (2007). *

• Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48: 458-473 (2008). *

• Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N,Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T. Tumour necrosis factor-alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424 (2006). *

• Tomiya T. Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatol. Res. 40: 108-110 (2010). *

• Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand. J. Gastroenterol. 42: 1095-1101 (2007). *

• Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698 (2008). *

• Tran TT. Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C, Capasso R, Coppola F, Dauria M, Loguercio C. The treatment of NAFLD. Eur. Rev. Med. Pharmacol. Sci. 9: 299-304 (2005).

• Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther. 13: 979-996 (1999). *

• Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am. J. Gastroenterol. 101: 2629-2640 (2006). *

• Tsuchiya H, Akechi Y, Ikeda R, Nishio R, Sakabe T, Terabayashi K, Matsumi Y, Ashla AA, Hoshikawa Y, Kurimasa A, Suzuki T, Ishibashi N, Yanagida S, Ganz T, Shiota G. Suppressive effects of retinoids on iron-induced oxidative stress in the liver. Gastroenterology 136: 341-350.e8 (2009). *

• Tsujimoto T, Kawaratani H, Kitazawa T, Yoshiji H, Fujimoto M, Uemura M, Fukui H. Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. World J. Gastroenterol. 15: 5533-5540 (2009). *

• Tsukamoto H, She H, Hazra S, Cheng J, Wang J. Fat paradox of steatohepatitis. J. Gastroenterol. Hepatol. 23 Suppl. 1: S104-S107 (2008). *

• Umar RK, Rinella ME. An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98 (2006). *

• Uno M, Kurita S, Misu H, Ando H, Ota T, Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, Nakanuma Y, Kaneko S, Takamura T. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology 48: 109-118 (2008). *

• Uraz S, Aygun C, Sonsuz A, Ozbay G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig. Dis. Sci. 50: 964-969 (2005). *

• Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martínez L, Pichardo-Bahena R, Baptista-Gonzalez HA, Ponciano-Rodriguez G, Uribe MH, Medina-Santillan R, Mendez-Sanchez N. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 7: 67-71 (2008). *

• Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol. Res. 32: 235-242 (2005).

• Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 95: 3584-3589 (2000). *

• Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, Loria P, Casiraghi MA, Suigo E, Ceriani R, Remondini E, Trombini P, Fargion S. alpha1-Antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology 44: 857-864 (2006). *

• Valenti L, Ludovica Fracanzani A, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin. Immunopathol. 31: 359-369 (2009). *

• van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin. Liver Dis. 12: 805-824, ix (2008).

• van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48: 449-457 (2008). *

• van Hoek B. Non-alcoholic fatty liver disease: a brief review. Scand. J. Gastroenterol. Suppl. 241: 56-59 (2004). *

• Varela NM, Quinones LA, Orellana M, Poniachik J, Csendes A, Smok G, Rodrigo R, Caceres DD, Videla LA. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol. Res. 41: 81-92 (2008). *

• Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49: 989-997 (2009). *

• Verdi H, Sare Koytak E, Onder O, Arslan Ergul A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. J. Investig. Med. 53: 353-359 (2005).

• Vial P, Riquelme A, Pizarro M, Solis N, Madariaga JA, Aguayo G, Duarte I, Soza A, Accatino L, Arrese M. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. Ann. Hepatol. 5: 25-29 (2006). *

• Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond.) 106: 261-268 (2004). *

• Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, Farese RV Jr. Specific role for acyl CoA:diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 50: 434-442 (2009).

• Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr. Drug Metab. 5: 273-282 (2004).

• Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann. Hepatol. 8: 89-94 (2009). *

• Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49: 306-317 (2009). *

• Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis?: a preliminary human study. J. Clin. Gastroenterol. 39: 237-242 (2005).

• Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid defined diet in C57BL/6 mice. Hepatology 50: 1152-1161 (2009). *

• Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int. J. Cancer 124: 540-546 (2008). *

• Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int. J. Cancer Jun 23 [Epub ahead of print] (2009). *

• Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 24: 99-106 (2004).

• Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol. 14: 193-199 (2008). *

• Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103: 1372-1379 (2008). *

• Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33 (2006). *

• Wiesinger HA, Shah J, White A, Yoshida EM, Frohlich J, Sirrs S, Gill S, Byrne MF. Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann. Hepatol. 7: 63-66 (2008). *

• Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206-211 (2001). *

• Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis. 27: 44-54 (2007). *

• Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM, Omenetti A, Jung Y, Teaberry V, Choi SS, Guy CD, Pollard J, Charlton P, Diehl AM. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50: 1421-1430 (2009).

• Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, Chim AM, Chu S, Chan FK, Sung JJ, Chan HL. Metabolic and histological features of nonalcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment. Pharmacol. Ther. 29: 387-396 (2009). *

• Wortham M, He L, Gyamfi M, Copple BL, Wan YJ. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 53: 2761-2774 (2008). *

• Wouters K, Bilsen MV, Gorp PJ, Bieghs V, Lutjohann D, Kerksiek A, Staels B, Hofker MH, Shiri-Sverdlov R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. Jan 28 [Epub ahead of print] (2010). *

• Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol. 14: 313-317 (2008). *

• Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. U.S.A. 102: 4120-4125 (2005). *

• Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig. Dis. Sci. May 21 [Epub ahead of print] (2009). *

• Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern. Med. J. 37: 229-235 (2007). *

• Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J. Gastroenterol. Hepatol. 22: 2009-2014 (2007). *

• Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366-1374 (2007). *

• Yamazaki Y, Kakizaki S, Horiguchi N, Sohara N, Sato K, Takagi H, Mori M, Negishi M. The role of nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 56: 565-574 (2007). *

• Yang L, Diehl AM. Chapter 26. Role of immune response in nonalcoholic fatty liver disease: evidence in human and animal studies. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 337-345 (2007). *

• Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challanges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther. 30: 1103-1109 (2009). *

• Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40: 1222-1225 (2004). *

• Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, Watanabe S, Hosono K, Mawatari H, Iida H, Fujita K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Kubota K, Shimamura T, Saito S, Maeyama S, Wada K, Nakajima A. Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol. Res. 39: 963-971 (2009). *

• Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42: 573-582 (2007). *

• Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 39: 1215-1218 (2004). *

• Younossi ZM, Afendy A, Stepanova M, Hossain N, Younossi I, Ankrah K, Gramlich T, Baranova A. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int. 29: 1403-1412 (2009).

• Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, Vanmeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42: 665-674 (2005). *

• Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18: 1430-1437 (2008).

• Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord. 2: 11-19 (2002). *

• Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, Hall P, Kirsch R, Leclercq I, Farrell GC. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43: 826-836 (2006). *

• Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Poon TC, Sung JJ. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int. J. Biochem. Cell. Biol. Feb 12 [Epub ahead of print] (2010). *

• Zamora-Valdes D, Mendez-Sanchez N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann. Hepatol. 6: 281-283 (2007). *

• Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, Denk H. The keratin cytoskeleton in liver diseases. J. Pathol. 204: 367-376 (2004). *

• Zen Y, Fujii T, Nakanuma Y. Hepatic pseudolymphoma: a clinicopathological study of five cases and review of the literature. Mod. Pathol. Nov 13 [Epub ahead of print] (2009).

• Zetterman RK. Clinical topics in liver disease. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51: 380-388 (2009).

• Zhang SJ, Chen ZX, Jiang KP, Cheng YH, Gu YL. The effect of QuYuHuaTanTongLuo decoction on the non-alcoholic steatohepatitis. Complement. Ther. Med. 16: 192-198 (2008).

• Zhang W, Kudo H, Kawai K, Fujisaka S, Usui I, Sugiyama T, Tsukada K, Chen N, Takahara T. Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem. Biophys. Res. Commun. Dec 28 [Epub ahead of print] (2009). *

• Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, Pacheco J, Piepenhagen P, Copeland D, Arbeeny C, Shayman JA, Aerts JM, Jiang C, Cheng SH, Yew NS. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50: 85-93 (2009).

• Zhou GD, Li MR, Zhang J, Pan D, Zhao SX, Yang JF, Yu J, Zhao JM. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol. 43: 1371-1377 (2008). *

Number of references = 635

www psc-literature.org